Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6534
    +0.0011 (+0.17%)
     

  • OIL

    83.93
    +0.36 (+0.43%)
     

  • GOLD

    2,346.60
    +4.10 (+0.18%)
     

  • Bitcoin AUD

    97,368.03
    -1,487.71 (-1.50%)
     

  • CMC Crypto 200

    1,324.00
    -72.53 (-5.19%)
     

  • AUD/EUR

    0.6106
    +0.0033 (+0.54%)
     

  • AUD/NZD

    1.0993
    +0.0035 (+0.32%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,753.50
    +322.99 (+1.85%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • Dow Jones

    38,305.41
    +219.61 (+0.58%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Why Supernus' Acquisition of Adamas Is a Smart Move

Keith Speights and Brian Orelli, PhD, The Motley Fool
·2-min read

Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS). In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acquisition of Adamas is a smart move.

Continue reading